Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors

Circulation

Volumn 113, Issue 6, 2006, Pages 867-875

  Campia, Umberto ^a   Matuskey, Linda A ^a   Panza, Julio A ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Atherosclerosis; Endothelium derived factors; Inflammation; Risk factors; Vasodilation

Indexed keywords

ACETYLCHOLINE; BRADYKININ; C REACTIVE PROTEIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL; VASODILATOR AGENT; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADULT; AGED; ARTERY DILATATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION; ADOLESCENT; CARDIOVASCULAR DISEASE; ENZYME ACTIVATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PPAR GAMMA; RISK FACTORS; THIAZOLIDINEDIONES; VASODILATION;

EID: 33644853793     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.549618     Document Type: Article

References (30)

1. Vane JR, Änggård EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27-36.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
3. Panza JA, Garcia C, Kilcoyne CM, Quyyumi AA, Cannon RO. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91:1732-1738.
4. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation. 1993;88:2541-2547.
5. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196.
6. Halcox JPJ, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
7. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes. Further evidence for the existence of the "vulnerable" patient. Circulation. 2004;110:1926-1932.
8. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol. 1999;84:11J-14J.
9. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
10. Campia U, Sullivan G, Bryant MB, Waclawiw MA, Quon MJ, Panza JA. Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. Am J Physiol. 2004;286:H76-H82.
11. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator activated receptor and atherogenesis: regulator of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
12. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
13. Lehman JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem. 1995;270:12953-12956.
14. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27:484-490.
15. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative Insulin-sensitivity Check Index (QUICKI): a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-2410.
16. Kiowski W, Linder L, Kleinbloesem C, van Brummelen P, Buhler FR. Blood pressure control by the renin-angiotensin system in normotensive subjects: assessment by angiotensin converting enzyme and renin inhibition. Circulation. 1992;85:1-8.
17. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle to acetylcholine. Nature. 1980;288:373-376.
18. Bohme E, Graf H, Schultz G. Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic-GMP formation in smooth muscles and platelets. Adv Cycl Nucl Res. 1978;9:131-143.
19. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon RO III. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation. 1994;90:35-41.
20. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
21. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394-402.
22. Calnek DS, Mazzella L, Roser S, Roman J, Hart MC. Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52-57.
23. Marx N, Mach F, Sauty A, Sarafi M, Libby P, Plutzky J, Luster AD. PPARγ activators inhibit interferon-γ-induced expression of the T cell active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164:6503-6508.
24. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, Takeshita A. Peroxisome proliferator-activated receptor activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834-1839.
25. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83:1097-1103.
26. Murakami T, Mizuno S, Ohsato K, Moriuchi I, Arai Y, Nio Y, Kaku B, Takahashi Y, Ohnaka M. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol. 1999;84:92-94.
27. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102:1000-1006.
28. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:717-726.
29. Chinetti G, Fruchard J-C, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptor at the crossroads between lipid metabolism and inflammation. Inflammation Res. 2000;49:497-505.
30. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941-2948.